BUSINESS-WIRE
2.4.2018 15:02:08 CEST | Business Wire | Press release
Business Wire and TrendKite have entered into a reciprocal sales arrangement, enabling clients to leverage the industry’s most comprehensive news distribution platform and then gauge the effectiveness of their campaign using the advanced analytics of TrendKite’s Intelligent Communications Platform .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180402005104/en/
The agreement brings together two influential service providers serving the public relations industry: Business Wire, the global leader in press release distribution, and TrendKite, a startup that has upended the legacy monitoring industry with its technological innovation and data-driven approach to quantifying media outreach results.
Business Wire and TrendKite will offer select service offerings under the terms of the agreement.
TrendKite clients will have the opportunity to reach audiences worldwide via Business Wire, which provides access to dozens of international and national news agencies, as well as leading financial information platforms, news syndicators, content aggregation services and databases.
Business Wire clients will be able to take advantage of the TrendKite Intelligent Communications Platform to measure the effectiveness of their press releases and public relations campaigns and identify and target key journalists and influencers to pitch. TrendKite helps organizations make better data-informed decisions about their communications programs and measure the business impact and bottom line results of their earned media. TrendKite’s innovative services transform 4.7 million global sources into actionable intelligence with customized dashboards, interactive reports, social amplification, Google and Adobe Analytics integrations and PR Attribution , which assesses the true impact of a media mention by measuring site traffic influenced by earned media. Going a step further, TrendKite has created Pinpoint Contacts, an artificial intelligence-powered influencer and journalist database, to assist communicators in identifying relevant contacts.
“TrendKite is a forward-thinking company that is aligned with Business Wire’s perspective on the future of content delivery and monitoring solutions,” said Geff Scott , Business Wire’s chief executive officer. “Our relationship with TrendKite promises to bring value to clients of both companies, providing best-of-breed solutions that will create new industry standards.”
“Our customers rely on news distribution as part of their plan to take a story to market, but have trouble knowing if their press releases are gaining earned coverage that drives business results,” said Erik Huddleston, TrendKite’s chief executive officer. “Business Wire’s status as the industry leader, combined with their measurably superior results and their understanding of the earned media landscape, make them a natural partner for TrendKite and a high value for our customers.”
About Business Wire:
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure . Investor relations, public relations, public policy and marketing professionals rely on Business Wire to accurately distribute market-moving news and multimedia, host online newsrooms and IR websites , build content marketing platforms , generate social engagements and provide audience analysis that improves interaction with specified target markets. Founded in 1961, Business Wire is a trusted source for news organizations, journalists, investment professionals and regulatory authorities, delivering news directly into editorial systems and leading online news sources via its multi-patented NX Network. Business Wire has 29 offices worldwide to securely meet the varying needs of communications professionals and news consumers.
Learn more at services.BusinessWire.com and Tempo , the Business Wire resource for industry trends; follow updates on Twitter: @businesswire or on Facebook .
About TrendKite
Founded in 2012 in Austin, Texas, TrendKite is the Intelligent Communications Platform that puts earned media at the heart of the marketing mix. By harnessing artificial intelligence and big data analytics to optimize the impact public relations has on a brand’s reputation, website traffic and business goals, TrendKite is transforming the way the world views earned media.
As a venture backed, high traction startup, TrendKite is disrupting a huge existing market while helping companies like Nike, Google, Delta, SXSW and thousands more turn PR coverage into real business impact.
Click here to subscribe to Mobile Alerts for Business Wire .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005104/en/
Contact:
TrendKite
Lacey Miller
lacey@trendkite.com
or
Business
Wire
Neil Hershberg, +1 212-752-9600, Ext. 1434
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom